Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 15/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19355282 | 0.91 | PRKDC (0.53) | PRKDCSLC40A1FAAH | |
| SCHEMBL15339608 | 0.90 | PRKDC (0.54) | PRKDCSLC40A1FAAH | |
| SCHEMBL17634688 | 0.90 | PRKDC (0.48) | PRKDCSLC40A1FAAH | |
| SCHEMBL17634795 | 0.90 | PRKDC (0.54) | PRKDCSLC40A1FAAH | |
| SCHEMBL15339663 | 0.89 | PRKDC (0.53) | PRKDCSLC40A1FAAH | |
| SCHEMBL15339677 | 0.89 | PRKDC (0.53) | PRKDCSLC40A1FAAH | |
| SCHEMBL15339617 | 0.89 | PRKDC (0.51) | PRKDCSLC40A1FAAH | |
| SCHEMBL15339616 | 0.89 | PRKDC (0.51) | PRKDCSLC40A1FAAH | |
| SCHEMBL15328700 | 0.89 | PRKDC (0.63) | PRKDCSLC40A1FAAH | |
| SCHEMBL15339664 | 0.89 | PRKDC (0.55) | PRKDCSLC40A1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| US-10442791-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-15 | — | — | US | disclosed |
| US-10391095-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-27 | — | — | US | disclosed |
| US-9925188-B2 | DNA-PK inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925188-B2 | DNA-PK inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-27 | — | — | US | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | disclosed |
| US-9376448-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376448-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-28 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
| US-10442791-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
| US-10391095-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
| US-11021465-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.